Prioritizing Development A Cost Benefit Analysis of the United Nations' Sustainable Development Goals
Book contents
- Prioritizing Development
- Prioritizing Development
- Copyright page
- Contents
- Figures
- Tables
- Boxes
- Contributors
- Foreword
- Introduction
- Chapter 1 Benefits and Costs of Air Pollution Targets for the Post-2015 Development Agenda
- Chapter 2 Targets for Biodiversity and Deforestation
- Chapter 3 Benefits and Costs of the Climate Change Targets for the Post-2015 Development Agenda
- Chapter 4 Beyond Civil War
- Chapter 5 Data Revolution
- Chapter 6 Benefits and Costs of the Education Targets for the Post-2015 Development Agenda
- Chapter 7 Benefits and Costs of the Energy Targets for the Post-2015 Development Agenda
- Chapter 8 Benefits and Costs of the IFF Targets for the Post-2015 Development Agenda
- Chapter 9 Benefits and Costs of the Trade Targets for the Post-2015 Development Agenda
- Chapter 10 Benefits and Costs of the Health Targets for the Post-2015 Development Agenda
- Chapter 11 Benefits and Costs of the Noncommunicable Disease Targets for the Post-2015 Development Agenda
- Chapter 12 Benefits and Costs of the Women’s Health Targets for the Post-2015 Development Agenda
- Chapter 13 Benefits and Costs of TB Control for the Post-2015 Development Agenda
- Chapter 14 Benefits and Costs of the Infant Mortality Targets for the Post-2015 Development Agenda
- Chapter 15 Benefits and Costs of the HIV/AIDS Targets for the Post-2015 Development Agenda
- Chapter 16 Benefits and Costs of the Malaria Targets for the Post-2015 Consensus Project
- Chapter 17 Benefits and Costs of Digital Technology
- Chapter 18 Returns to Investment in Reducing Postharvest Food Losses and Increasing Agricultural Productivity Growth
- Chapter 19 Benefits and Costs of the Gender Equality Targets for the Post-2015 Development Agenda
- Chapter 20 Benefits and Costs of the Food and Nutrition Targets for the Post-2015 Development Agenda
- Chapter 21 Benefits and Costs of the Population and Demography Targets for the Post-2015 Development Agenda
- Chapter 22 Benefits and Costs of Two Science and Technology Targets for the Post-2015 Development Agenda
- Chapter 23 Global Benefits and Costs of Achieving Universal Coverage of Basic Water and Sanitation Services as part of the 2030 Agenda for Sustainable Development
- Chapter 24 Benefits and Costs of the Poverty Targets for the Post-2015 Development Agenda
- Chapter 25 Good Governance and the Sustainable Development Goals
- Conclusion
- Index
- References
Chapter 12 - Benefits and Costs of the Women’s Health Targets for the Post-2015 Development Agenda
Published online by Cambridge University Press: 30 May 2018
Book contents
- Prioritizing Development
- Prioritizing Development
- Copyright page
- Contents
- Figures
- Tables
- Boxes
- Contributors
- Foreword
- Introduction
- Chapter 1 Benefits and Costs of Air Pollution Targets for the Post-2015 Development Agenda
- Chapter 2 Targets for Biodiversity and Deforestation
- Chapter 3 Benefits and Costs of the Climate Change Targets for the Post-2015 Development Agenda
- Chapter 4 Beyond Civil War
- Chapter 5 Data Revolution
- Chapter 6 Benefits and Costs of the Education Targets for the Post-2015 Development Agenda
- Chapter 7 Benefits and Costs of the Energy Targets for the Post-2015 Development Agenda
- Chapter 8 Benefits and Costs of the IFF Targets for the Post-2015 Development Agenda
- Chapter 9 Benefits and Costs of the Trade Targets for the Post-2015 Development Agenda
- Chapter 10 Benefits and Costs of the Health Targets for the Post-2015 Development Agenda
- Chapter 11 Benefits and Costs of the Noncommunicable Disease Targets for the Post-2015 Development Agenda
- Chapter 12 Benefits and Costs of the Women’s Health Targets for the Post-2015 Development Agenda
- Chapter 13 Benefits and Costs of TB Control for the Post-2015 Development Agenda
- Chapter 14 Benefits and Costs of the Infant Mortality Targets for the Post-2015 Development Agenda
- Chapter 15 Benefits and Costs of the HIV/AIDS Targets for the Post-2015 Development Agenda
- Chapter 16 Benefits and Costs of the Malaria Targets for the Post-2015 Consensus Project
- Chapter 17 Benefits and Costs of Digital Technology
- Chapter 18 Returns to Investment in Reducing Postharvest Food Losses and Increasing Agricultural Productivity Growth
- Chapter 19 Benefits and Costs of the Gender Equality Targets for the Post-2015 Development Agenda
- Chapter 20 Benefits and Costs of the Food and Nutrition Targets for the Post-2015 Development Agenda
- Chapter 21 Benefits and Costs of the Population and Demography Targets for the Post-2015 Development Agenda
- Chapter 22 Benefits and Costs of Two Science and Technology Targets for the Post-2015 Development Agenda
- Chapter 23 Global Benefits and Costs of Achieving Universal Coverage of Basic Water and Sanitation Services as part of the 2030 Agenda for Sustainable Development
- Chapter 24 Benefits and Costs of the Poverty Targets for the Post-2015 Development Agenda
- Chapter 25 Good Governance and the Sustainable Development Goals
- Conclusion
- Index
- References
Summary
Economists have long recognized the positive association between population health and income per capita. Traditionally, this association was viewed as reflective of a causal link from income to health. In recent years, robust evidence has been offered in support of the view that the association also reflects a reverse causal link from population health to income. However, this growing body of research has yet to identify the specific and essential role of women’s health as a driver of economic growth. We believe that there are strong reasons to believe that female-specific health interventions are a sound investment for promoting economic well-being at both individual and population levels. In particular, we focus on vaccination against human papilloma virus (HPV), largely motivated by the substantial cervical cancer burden borne by women in resource-poor countries during what is often the most productive years of their lives.
- Type
- Chapter
- Information
- Prioritizing DevelopmentA Cost Benefit Analysis of the United Nations' Sustainable Development Goals, pp. 244 - 254Publisher: Cambridge University PressPrint publication year: 2018
References
Agosti, JM, Goldie, SJ. 2007. Introducing HPV vaccine in developing countries – key challenges and issues. New England Journal of Medicine 356(19):1908–10.CrossRefGoogle ScholarPubMed
Arbyn, M, Anttila, A, Jordan, J, et al. 2010. European Guidelines for Quality Assurance in Cervical Cancer Screening. Second edition – summary document. Annals of Oncology 21(3):448–58.Google Scholar
Arbyn, M, Castellsagué, X, de Sanjosé, S, et al. 2011. Worldwide burden of cervical cancer in 2008. Annals of Oncology 22(12):2675–86.CrossRefGoogle ScholarPubMed
Arrossi, S, Matos, E, Zengarini, N, et al. 2007. The socio-economic impact of cervical cancer on patients and their families in Argentina, and its influence on radiotherapy compliance. Results from a cross-sectional study. Gynecologic Oncology 105(2):335–40.Google Scholar
Averbach, SH, Gravitt, PE, Nowak, RG, et al. 2010. The association between cervical human papillomavirus infection and HIV acquisition among women in Zimbabwe. AIDS 24(7):1035–42.Google Scholar
Brewer, NT, Cuite, CL, Herrington, JE, Weinstein, ND. 2007. Risk compensation and vaccination: can getting vaccinated cause people to engage in risky behaviors? Annals of Behavioral Medicine 34(1):95–9.CrossRefGoogle ScholarPubMed
Centers for Disease Control (CDC). 2013. Human papillomavirus (HPV) vaccine. www.cdc.gov/vaccinesafety/vaccines/HPV/index.html. Accessed November 13, 2014.Google Scholar
Chen, MK, Hung, HF, Duffy, S, Yen, AM, Chen, HH. 2011. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination. Journal of Evaluation in Clinical Practice 17(6):1050–8.CrossRefGoogle ScholarPubMed
Chesson, HW, Forhan, SE, Gottlieb, SL, Markowitz, LE. 2008. The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26(35):4513–8.Google Scholar
Denny, L, Quinn, M, Sankaranarayanan, R. 2006. Chapter 8: Screening for cervical cancer in developing countries. Vaccine 24 Suppl 3:S3/71–7.CrossRefGoogle ScholarPubMed
Diaz, M, Kim, JJ, Albero, G, et al. 2008. Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening. India British Journal of Cancer 99: 230–238.CrossRefGoogle ScholarPubMed
Ferlay, J, Soerjomataram, I, Ervik, M, et al. 2013. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide. IARC CancerBase. http://globocan.iarc.fr. Accessed November 13, 2014.Google Scholar
Fregnani, JH, Carvalho, AL, Eluf-neto, J, et al. 2013. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS ONE 8(4):e62647.Google Scholar
Alliance, GAVI. 2014. 206,000 more girls to benefit from HPV vaccine with GAVI Alliance support. 10 countries approved in latest round of HPV vaccine demonstration programmes. www.gavi.org/library/news/press-releases/2014/206-000-more-girls-to-benefit-from-hpv-vaccine-with-gavi-alliance-support/. Accessed January 11, 2018.Google Scholar
Gakidou, E, Nordhagen, S, Obermeyer, Z. 2008. Coverage of cervical cancer screening in 57 countries: low average levels and large inequalities. PLOS Medicine 5(6):e132.Google Scholar
Ginsberg, GM, Tan-Torres Edejer, T, Lauer, JA, Sepulveda, C. 2009. Screening, prevention and treatment of cervical cancer – a global and regional generalized cost-effectiveness analysis. Vaccine 27(43): 6060–79.Google Scholar
Goldie, SJ, Kim, JJ, Kobus, K, et al. 2007. Cost-effectiveness of HPV 16, 18 vaccination in Brazil. Vaccine 25(33):6257–70.Google Scholar
Goldie, SJ, O’Shea, M, Campos, NG, et al. 2008. Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries. Vaccine 26(32):4080–93.CrossRefGoogle ScholarPubMed
Greimel, ER, Winter, R, Kapp, KS, Haas, J. 2009. Quality of life and sexual functioning after cervical cancer treatment: a long-term follow-up study. Psychooncology 18(5):476–82.CrossRefGoogle ScholarPubMed
Gustafsson, L, Pontén, J, Zack, M, Adami, HO. 1997. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes and Control 8(5):755–63.Google Scholar
Jayachandran, S and Lleras-Muney, A. 2009. Life expectancy and human capital investments: Evidence from maternal mortality declines. National Bureau of Economic Research 124 (1): 349–97.Google Scholar
Jit, M, Brisson, M, Portnoy, A, Hutubessy, R. 2014. Cost-effectiveness of female human papillomavirus vaccination in 179 countries: a PRIME modelling study. Lancet Global Health 2(7):e406–14.Google Scholar
John, TJ, Samuel, R. 2000. Herd immunity and herd effect: new insights and definitions. European Journal of Epidemiology 16(7):601–6.Google Scholar
Kim, JJ, Andres-Beck, B, Goldie, SJ. 2007. The value of including boys in an HPV vaccination programme: a cost-effectiveness analysis in a low-resource setting. British Journal of Cancer 97(9):1322–8.Google Scholar
Kim, JJ, Goldie, SJ. 2009. Cost effectiveness analysis of including boys in a human papillomavirus vaccination programme in the United States. BMJ 339:b3884.Google Scholar
Kim, JJ, Kobus, KE, Diaz, M, et al. 2008. Exploring the cost-effectiveness of HPV vaccination in Vietnam: insights for evidence-based cervical cancer prevention policy. Vaccine 26(32):4015–24.CrossRefGoogle ScholarPubMed
Kim, JJ, Kobus, KE, O’Shea, M, et al. 2007. Impact of HPV vaccine duration and efficacy on cost-effectiveness of vaccination in Vietnam [Abstract: PS19–35]. In: Proceedings of the 24th International Papillomavirus Conference and Clinical Workshop. Beijing, China: CNKI.Google Scholar
Kreimer, AR, Rodriguez, AC, Hildesheim, A, et al. 2011. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. Journal of the National Cancer Institute 103(19):1444–51.CrossRefGoogle ScholarPubMed
Light, DW. 2006. Pricing pharmaceuticals in USA. In: Temple, NJ and Thompson, A, eds. Excessive medical spending: facing the challenge. London: Radcliffe Publishing, 63–99.Google Scholar
Lu, B, Kumar, A, Castellsagué, X, Giuliano, AR. 2011. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infectious Diseases 11:13.CrossRefGoogle ScholarPubMed
Lydon, P, Levine, R, Makinen, M, et al. 2008. Introducing new vaccines in the poorest countries: what did we learn from the GAVI experience with financial sustainability? Vaccine 26(51):6706–16.Google Scholar
Markowitz, LE, Dunne, EF, Saraiya, M, Lawson, H, Chesson, H, Unger, ER. 2007. Quadrivalent Human Papillomavirus Vaccine Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. http://origin.glb.cdc.gov/MMWR/preview/mmwrhtml/rr5602a1.html. Accessed November 13, 2014.Google Scholar
Markowitz, LE, Tsu, V, Deeks, SL, et al. 2012. Human papillomavirus vaccine introduction – the first five years. Vaccine 30 Suppl 5:F139–48.Google Scholar
Marlow, LA, Forster, AS, Wardle, J, Waller, J. 2009. Mothers’ and adolescents’ beliefs about risk compensation following HPV vaccination. Journal of Adolescent Health 44(5):446–51.Google Scholar
Masia, N. 2008. The cost of developing a new drug. IIP Digital. http://iipdigital.usembassy.gov/st/english/publication/2008/04/20080429230904myleen0.5233981.html#axzz3Iy3tAKMB. Accessed November 13, 2014.Google Scholar
Miller, AB, Nazeer, S, Fonn, S, et al. 2000. Report on consensus conference on cervical cancer screening and management. International Journal of Cancer 86(3):440–7.3.0.CO;2-A>CrossRefGoogle ScholarPubMed
Newall, AT, Beutels, P, Wood, JG, Edmunds, WJ, Macintyre, CR. 2007. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infectious Diseases 7(4):289–96Google Scholar
Pomfret, TC, Gagnon, JM, Gilchrist, AT. 2011. Quadrivalent human papillomavirus (HPV) vaccine: a review of safety, efficacy, and pharmacoeconomics. Journal of Clinical Pharmacy and Therapeutics 36(1):1–9.Google Scholar
Qureshi, S, Das, V, Zahra, F. 2010. Evaluation of visual inspection with acetic acid and Lugol’s iodine as cervical cancer screening tools in a low-resource setting. Tropical Doctor 40(1):9–12.Google Scholar
Read, TR, Hocking, JS, Chen, MY, et al. 2011. The near disappearance of genital warts in young women 4 years after commencing a national human papillomavirus (HPV) vaccination programme. Sexually Transmitted Infections 87(7):544–7.Google Scholar
Roberts, RR, Mensah, EK, Weinstein, RA. 2010. A guide to interpreting economic studies in infectious diseases. Clinical Microbiology and Infection 16(12):1713–20.CrossRefGoogle ScholarPubMed
Saleh, HS. 2013. Can visual inspection with acetic acid be used as an alternative to Pap smear in screening cervical cancer? Middle East Fertility Society Journal 19(3): 187–91.Google Scholar
Saslow, D, Castle, PE, Cox, JT, et al. 2007. American Cancer Society Guideline for human papillomavirus (HPV) vaccine use to prevent cervical cancer and its precursors. CA: A Cancer Journal for Clinicians 57(1):7–28.Google Scholar
Schiffman, M, Castle, PE, Jeronimo, J, Rodriguez, AC, Wacholder, S. 2007. Human papillomavirus and cervical cancer. Lancet 370(9590):890–907.Google Scholar
Smith, JS, Moses, S, Hudgens, MG, et al. 2010. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. Journal of Infectious Diseases 201(11):1677–85.Google Scholar
Taira, AV, Neukermans, CP, Sanders, GD. 2004. Evaluating human papillomavirus vaccination programs. Emerging Infectious Diseases 10(11):1915–23.Google Scholar
Van Kriekinge, G, Castellsagué, X, Cibula, D, Demarteau, N. 2014. Estimation of the potential overall impact of human papillomavirus vaccination on cervical cancer cases and deaths. Vaccine 32(6): 733–739.Google Scholar
Venkatesan, NN, Pine, HS, Underbrink, MP. 2012. Recurrent respiratory papillomatosis. Otolaryngologic Clinics of North America 45(3):671–94, viii–ix.Google Scholar
World Health Organization (WHO). 2007. Human papillomavirus and HPV vaccines: technical information for policy-makers and health professionals. Geneva: WHO.Google Scholar
World Health Organization (WHO). 2013. Global action plan for the prevention and control of noncommunicable diseases 2013–2020. Geneva: WHO.Google Scholar
- 3
- Cited by